Catatonia is a psychomotor syndrome which can be characterised by concomittant motor and emotional abnormalities. 1 2 Patients show complete akinesia and intense and uncontrollable anxieties. 3 4 Several clinical studies have shown the therapeutic eYciacy of benzoiazepines. [4] [5] [6] [7] Lorazepam, a benzodiazepine, leads to potentiation of inhibition mediated by GABA-A receptors and alterations in density of GABA-A receptors in cortical motor areas may thus be assumed in akinetic catatonia.
The GABA-A receptors have never been studied in akinetic catatonia. We therefore investigated akinetic catatonic patients with single photon emission computed tomography (SPECT) using iodine-123-labelled iomazenil ( 123 I Iomazenil) as a radioligand that selectively binds with high aYnity to the benzodiazepine subunit of the GABA-A receptor complex in the human brain. Clinical studies in healthy volunteers have shown that it has a high brain uptake, relatively slow washout of radioactivity, a long half life, and appropriate regional distribution. 8 9 To exclude eVects of cerebral perfusion on iomazenil binding and distribution we additionally investigated regional cerebral blood flow (r-CBF) with Tc-99m ECD in the same subjects immediately after I-123-Iomazenil SPECT.
Methods

CATATONIC PATIENTS
We investigated 10 catatonic patients (six women, four men; mean age: 41.6 (SD 5.3) years; mean illness duration: 8.6 (SD 2.3) years; mean number of admissions to hospital: 3.5 (SD 0.9)) from psychiatric clinics Magdeburg, Haldensleben, and Blankenburg (incidence, calculated in relation to all incoming patients: 2.6%). No significant diVerences in psychopathological measurements and imaging results were found between neuroleptically treated (n=4; 5-20 mg haloperidol for 1.1 (SD 0.4) years) and neuroleptically naive (n=6) catatonic patients. In addition, patients were pretreated with antidepressant drugs (n=3; 50-200 mg amitryptilin), lithium (n=2; serum concentration: 0.9 mmol/l), and carbamazepin (n=1; serum concentration: 8 µg/ml), patients did not receive any benzodiazepines in the 6 months before admission (measurement of serum concentration of lorazepam according to the method of Greenlatt et al. 10 on days 0, 1, 4, and 8). Patients with chronic neurological or other physical illness, alcohol or other substance misuse, hyperkinesias, or dyskinesias as assessed with the abnormal involuntary movement scale (AIMS), 11 or neuroleptic induced movement disorders as assessed with the scale for extrapyramidal side eVects (SEPS) >3 12 were excluded from the study. Psychopathological assessment were made with the global assessment scale (GAS), 13 the positive and negative symptom scale (PANS), 14 the Hamilton anxiety scale (HAM-A), 15 and the Hamilton depresson scale (HAM-D) 16 on days 0, 1, and 8. All patients were right handed according to the Edinburgh Inventory of handedness. 17 Comorbid diagnoses were made according to DSM IV 18 on discharge showing the following diagnosis: catatonic schizophrenia (295.20: n=3); bipolar I disorder (296.04c: n=1); major depression (296.34c: n=1); bipolar I disorder (296.44c: n=2); bipolar I disorder (296.54c: n=3).
Catatonic syndrome (number of catatonic episodes during illness: 3.0 (SD 0.8); days of catatonic symptoms during current episode: 14.5 (SD 5.8) days) was diagnosed according to criteria by Lohr and Wisniewski (three from 11 symptoms), 19 Rosebush et al (four from 12 symptoms), 5 the Bush-Francis catatonia rating scale (BFCRS), 6 and the NorthoV catatonia scale (NCS). 20 21 Catatonic symptoms had to be manifest for at least half an hour on the day of admission in the presence of both examiners (GN; PD) who rated the same patients successively within 1 hour on days 0, 1, and 8. Only patients with akinetic (exclusion of hyperkinetic catatonia; see NorthoV et al 4 7 ) catatonia and reponse to lorazepam (single intravenous doses of 2 mg) in the first 24 hours 4 7 were included. In the next days all patients received no benzodiazepines but antidepressant (n=5) or neuroleptic drugs (n=8) until SPECT investigation, which took place on day 8.
CONTROL GROUPS
Two control groups were investigated: (1) an age and sex matched psychiatric control group (age: 40.8 (SD 4.9) years; all right handed) comprised patients with a similiar diagnosis, illness duration, exclusion criteria, and medication as catatonic patients but without catatonic syndrome. The medication and SPECT protocols were similar to the catatonic groups. (2) A healthy control group of 20 subjects (age: 40.1 (SD 6.2) years; all right handed) matched for age and sex. Subjects with a history of psychiatric, neurological, or serious physical illness, drug or alcohol misuse, or first degree relatives with major psychiatric or neurological disorders were excluded. Ethics permission was obtained from the ethics committee of the University of Magdeburg and the administration of radioactive substances advisory committee. Informed consent was obtained from all subjects.
IMAGING PROCEDURE AND DATA ANALYSIS Iomazenil was synthesised and labelled with 123 I at the Paul Scherrer Institute (Villingen, Switzerland) according to the method described by Beer et al. 22 SPECT was performed with a rotating gamma camera (Siemens, Diacam) with a low energy, high resolution collimator (FWHM: 7.5 mm at 10 cm depth). Subjects were positioned supine in a rigid, concave headrest of fixed height with respect to the gantry, and the imaging table was locked into position. Images were obtained at 64 projections in a 64×64 matrix acquisition (pixel size: 8 mm) over 360°, 40 seconds for each projection (revolution time: 40 minutes). The acquired frames were corrected for the injected dose and for the individual distribution volume by normalising to 1.73 m body surface. The eVective half life of iomazenil during SPECT acquisition was estimated by measuring the activity in a 60% isocontour at the start (mean of frame 1 to 3 during SPECT) and the remaining activity at the end of acquisition (last three planar images of the 64 projections).
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I iomazenil were given as a slow intravenous injection administered to the subject in a dimly lit, quiet room. 23 As rCBF has only minor eVects on delayed images of iomazenil binding 23 SPECT imaging started 120 minutes postinjection. To avoid circadian variablity, 24 the SPECT scans for all subjects were obtained at the same time of day (±30 minutes). Directly after finishing 123 I iomazenil SPECT Tc-99m ECD was injected in the same subjects to measure regional cerebral blood flow excluding blood flow eVects in iomazenil distribution and binding.
All subjects underwent MRI on a Siemens 1.5 Tesla system using the standard head coil. 10 contigous T1 weighted axial images (thickness: 4 mm, gap size: 0.3) were acquired up to planes parallel to the AC-PC line and coregistered with SPECT within the Siemens system to aid anatomical localisation and to exclude medium to severe brain atrophy, which was recently shown to significantly reduce r-CBF, RMRGlu values, and receptor density. 25 Images were reconstructed by filtered back projection using a Butterworth filter of order 7 and a cut oV frequency of 0.6 cm -1
. Transverse slices were reoriented to the canthomeatal line using an external line source for landmarking. Slices in the other two orthogonal planes were then reangulated. The spatial resolution was 15 mm (full width half maximum (FWHM)) in the transaxial plane. Sixty four axial slices (exclusion of the most basal and the most dorsal slices), 1.66 mm thick, were reconstructed by using a filter with a cut oV frequency of 0.6 cycles per pixel, and corrected for attenuation with a uniform linear attenuation correction coeYcient of 0.12 cm -1
. Regions of interest (ROIs) were determined using the anatomical atlases of Talairach and Tournoux   26   and  Kretschmann and Weinrich; 27 corresponding ROIs of all slices were summed together and defined as follows: lower medial and lateral prefrontal cortex, lower frontal cortex, upper and lower temporal cortex, middle medial and lateral prefrontal cortex, middle frontal cortex, lower and upper parietal cortex, upper frontal cortex (which predominantly encomprises the sensorimotor cortex), and upper medial and lateral prefrontal cortex, each on the right and left hemisphere. All ROIs were larger than 2.5×FWHM (15 mm) of our camera to allow a secure quantification. 28 Average counts per pixel from each region were used for analysis.The activity measured in each ROI was divided by the activity obtained in the occipital maximum (occipital ratio), which corresponds to the 80% isocontour of the maximum value in the respective slice. The occipital maximum was obtained by averaging occipital activity from all slices. 29 We used the occipital maximum and not the cerebellum as a reference region as in catatonia the cerebellum may itself be abnormal. 30 31 Comparison of occipital maxima between catatonic patients and the other groups showed no significant differences (p>0.05). In addition to occipital ratios, we calculated whole brain ratios. Activities from each ROI were therefore normalised by dividing them by whole brain activity which by itself was obtained as averaged counts of all reconstructed slices in the brain.
All images were analysed blindly by two independent raters (CZ; RS). The intraobserver variability determined for single ROIs in all groups was lower than 3% (<1 SD of the ROI values). The interobserver variability for single ROIs in 20 patients was <4% (<1SD). All ROI values showed no significant deviations from normal distribution (Shapiro-Wilks test, Lilliefors test, p>0.05) so that diVerences of more than 2 SD between the three groups were considered abnormal. Intrarater and interrater reliabilities were evaluated and Kendall's coeYcients of correlation were found to be above 0.87.
STATISTICAL ANALYSIS
Regional diVerences between groups were calculated using repeated measures analysis of variance (ANOVA) with one between subjects factor (groups) and one within subject factor (regions of interest) applying post hoc t tests with Bonferroni corrections for multiple comparisons.
Right-left diVerences were calculated in three ways: (1) global right-left diVerences in a repeated measurement ANOVA with one between subject factor (group) and two within subjects factors (regions of interest, level (upper, middle, lower)); (2) right-left diVerences for each region of interest were analysed in univariate t tests; (3) 
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Relations between clinical/psychopathological data and iomazenil binding in the various regions of interest were calculated using parametric Pearson correlations.
Results
IOMAZENIL BINDING
Catatonic patients showed significantly lower iomazenil binding in the left upper frontal cortex (which predominantly encomprises the sensorimotor cortex) than psychiatric (p<0.001) and healthy (p<0.001) controls (table 1 and figure). Both catatonic patients and psychiatric controls showed significantly lower iomazenil binding in the right and left lower (and upper) prefrontal cortex (p<0.001) than healthy controls (table 1) . Iomazenil binding in parietal and temporal cortex 33 and cerebellum did not diVer significantly between groups.
Global right-left diVerences were significant at the lower and upper level in catatonia (p=0.0001-0.004) and in the lower level in psychiatric controls (p=0.0001) whereas there were no significant right-left diVerences in healthy controls. Regional right-left alterations were significant (p<0.001) in the upper frontal cortex and lower medial and lateral prefrontal cortex in catatonia and in the lower medial and lateral prefrontal cortex (but not in the upper frontal cortex) in psychiatric controls. Unlike healthy controls, both catatonic patients and psychiatric controls showed right-left diVerences in the lower medial and lateral prefrontal cortex. This is further underlined by calculation of right-left diVerences in multivariate analysis. Significant eVects of regions (F=15.958; df=4.00; p=0.000), levels (F=12.519; df=3.00; p=0.000), and groups (F=6.927; df=3.00; p=0.001) were found. The level by group interaction (F=4.059; df=6.00; p=0.002) and the region by group interaction (F=2.390; df=8.00; p=0.034) were significant.
PERFUSION (R-CBF)
Values that diVered between groups are shown in table 2. r-CBF in the left upper frontal Global right-left diVerences were significant at the lower level in healthy controls (p=0.004-0.012) and at all levels (upper, middle, lower) in catatonic patients (p=0.000-0.023) whereas there were no significant right-left diVerences at any level in psychiatric controls. Catatonic patients showed significant (p<0.001) rightleft alterations in the lower and middle medial and lateral prefrontal cortex as well as in the lower parietal cortex whereas in healthy controls significant right-left diVerences were found only in the prefrontal but not in the parietal cortex. This is further underlined by calculation of right-left diVerences in multivariate analysis. Significant eVects of regions (F=12.44; df=4.00; p=0.000) and groups (F=10.95; df=2.43; p=0.005) were shown. The group by region interaction was significant (F=3.14; df=8.88; p=0.006). Several studies showed immediate therapeutic eVects of lorazepam, a GABA-A potentiator, in akinetic catatonia. [5] [6] [7] We therefore assumed alterations in density of GABA-A receptors in cortical motor and premotor areas in pathophysiology of akinesia in catatonia. 2 4 7 34 The present study showed reduced iomazenil binding and altered rightleft relations in the left sensorimotor cortex in akinetic catatonia suggesting a decrease in the density of GABA-A receptors in the primary motor cortex. This finding is further supported by the following observations: (1) no reduction of r-CBF in the left sensorimotor cortex so that eVects of r-CBF on iomazenil binding are rather unlikely; (2) reversal of therapeutic eVects of lorazepam on akinesia by GABA-A antagonists (for example, Ro 15-1788) with reoccurence of catatonic symptoms; 35 (3) therapeutic eYciacy of electroconvulsive therapy in akinetic catatonia which, similarly to benzodiazepines, is sought to act via the GABA system; 2 34 (4) injection of GABA-A receptor agonists (for example, muscimol) into the motor cortex in monkeys leads to catatonic-like alterations in movements (akinesia, posturing) which could be reversed by GABA-A antagonists (for example, biccuculline; [36] [37] [38] ; (5) delayed (within 2-4 hours) therapeutic eVects of amantadine in akinetic catatonia 39 which, via blockade of excitatory NMDA-receptors, indirectly strengthens cortical inhibition.
In addition, we found an opposite relation of motor and aVective symptoms in catatonia with left sensorimotor cortical iomazenil binding. Motor symptoms correlated positively whereas aVective alterations showed negative correlations. Considering the positive correlation, therapeutic eVects of lorazepam in catatonia seem rather paradoxical as increase of GABA-ergic mediated inhibition should then go along with an increase of motor symptoms. However, aVective catatonic symptoms showed an inverse correlation with sensorimotor and prefrontal cortical iomazenil binding so that lorazepam may modulate motor symptoms and GABA-ergic function in the motor cortex via aVective and prefrontal GABA-ergic regulation. 40 Such an assumption of a close pathophysiological relation between motor and aVective symptoms in catatonia would be supported by the following observations: (1) significant correlations of aVective and motor symptoms with both prefrontal and frontal cortical iomazenil binding in catatonia; (2) a close relation between emotions and movements in subjective experience of akinetic catatonic patients who, unlike parkinsonian patients, retrospectively report rather about intense and uncontrollable anxieties than about movement disturbances 4 ; (3) lorazepam shows immediate therapeutic eYciacy only in catatonic patients with strong emotional alterations whereas those with less aVective symptoms do not respond to lorazepam. 4 7 Similarly to other studies [41] [42] [43] we found deficits of r-CBF in the right parietal cortex [41] [42] [43] which, in addition, correlated significantly with catatonic motor and aVective symptoms. The parietal cortex has been found to be involved in motor attention and preparation of movements [44] [45] [46] both showing specific alterations in catatonia: (1) catatonic patients are not aware of movement disturbances whereas they are fully aware of emotional alterations 4 which may be interpreted as a deficit in motor attention; (2) catatonic patients show deficits in the preparation of movements 3 ; (3) observation of catatonic-like posturing in patients with isolated lesions in right parietal cortex 47 48 ; (4) significant impairment in visual-spatial functions, as measured with the visual-spatial object perception test, which is particuarly sensitive to right parietal cortical lesions, in catatonia. 49 However, the exact pathophysiological relation of r-CBF deficits in the right parietal and right prefrontal cortex with decreased iomazenil-binding in the left sensorimotor cortex remains unclear so that specific investigation of motor attention and preparation is necessary in catatonia.
